BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Lecanemab becomes the first the medicine which targets an underlying cause of the disease, to be authorized in a country in Europe.

An alternate dosing plan for donanemab reduced that risk of ARIA-E down to more in line with that for lecanemab while still maintaining sufficient amyloid reduction in early Alzheimer's disease in ...

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this ...

Lecanemab is the only approved Aβ monoclonal antibody that preferentially binds and clears toxic protofibrils ** (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques ...